Rapid compensatory changes in the expression of EAAT-3 and GAT-1 transporters during seizures in cells of the CA1 and dentate gyrus by Laura Medina-Ceja et al.
Medina-Ceja et al. Journal of Biomedical Science 2012, 19:78
http://www.jbiomedsci.com/content/19/1/78RESEARCH Open AccessRapid compensatory changes in the expression of
EAAT-3 and GAT-1 transporters during seizures in
cells of the CA1 and dentate gyrus
Laura Medina-Ceja*, Flavio Sandoval-García, Alberto Morales-Villagrán and Silvia J López-PérezAbstract
Background: Epilepsy is a neurological disorder produced by an imbalance between excitatory and inhibitory
neurotransmission, in which transporters of both glutamate and GABA have been implicated. Hence, at different
times after local administration of the convulsive drug 4-aminopyridine (4-AP) we analyzed the expression of
EAAT-3 and GAT-1 transporter proteins in cells of the CA1 and dentate gyrus.
Methods: Dual immunofluorescence was used to detect the co-localization of transporters and a neuronal marker.
In parallel, EEG recordings were performed and convulsive behavior was rated using a modified Racine Scale.
Results: By 60 min after 4-AP injection, EAAT-3/NeuN co-labelling had increased in dentate granule cells and
decreased in CA1 pyramidal cells. In the latter, this decrease persisted for up to 180 min after 4-AP administration.
In both the DG and CA1, the number of GAT-1 labeled cells increased 60 min after 4-AP administration, although
by 180 min GAT-1 labeled cells decreased in the DG alone. The increase in EAAT-3/NeuN colabelling in DG was
correlated with maximum epileptiform activity and convulsive behavior.
Conclusions: These findings suggest that a compensatory mechanism exists to protect against acute seizures
induced by 4-AP, whereby EAAT-3/NeuN cells is rapidly up regulated in order to enhance the removal of glutamate
from the extrasynaptic space, and attenuating seizure activity.
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Epilepsy is a neurological disease with a lifetime prevalence of
2-5% (excluding febrile seizures), affecting approximately 67
million people worldwide [1]. Epilepsy is thought to reflect an
imbalance between excitatory and inhibitory neurotransmis-
sion [2,3] and indeed increased levels of glutamate, the princi-
pal excitatory neurotransmitter in the central nervous system
(CNS), have been well documented during seizures [2,4]. This
excess glutamate must be removed from the synaptic space
by membrane proteins called transporters. At least five sub-
types of glutamate transporters have been described, along
with several variants: GLAST (EAAT-1), GLT-1 (EAAT-2,
EAAT-2a, EAAT-2b and EAAT-2c), EAAC-1(EAAT-3),
EAAT-4 and EAAT-5 [5-7]. Glutamate transporters are* Correspondence: lmedina@cucba.udg.mx
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distribution, and reproduction in any mediumexpressed by neurons and glial cells in many regions of the
brain and for example, the EAAT-3 transporter is expressed
in the dendrites and soma of granule and pyramidal cells of
the hippocampal dentate gyrus and CA1 region, respectively.
Moreover, EAAT-3 transporters are found at both asymmet-
ric and symmetric synapses [8-10]. In conjunction with the
cysteine/glutamate antiporter Xc
-, EAAT-3 protects neuronal
HT22 cells (an immortalized hippocampal cell line) from oxi-
dative glutamate toxicity [11]. Indeed, altered EAAT-3 expres-
sion has been described in epilepsy and in response to
particular seizure types. Accordingly, in a pilocarpine-induced
rat model of Temporal Lobe Epilepsy (TLE), EAAT-3 gene
and protein expression increases rapidly in dentate granule
cells in association with long-lasting epilepsy [12]. Similar
findings have been reported in TLE patients [13-15], in whom
an increase in EAAT-3 protein levels and in the percentage of
EAAT-3-IR neurons occurs in CA2 and in the granule cell
layer of the dentate gyrus.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tory neurotransmitter, is also thought to play an important
role in epilepsy and four GABA transporter subtypes have
been identified in mammals: GAT-1, GAT-2, GAT-3 and
GAT-4 [16]. In particular, GAT-1 is expressed in the pyr-
amidal and granule cell layers of the hippocampal forma-
tion, and this transporter is considered therapeutically
significant given the antiepileptic effects elicited by its
blockade [17,18]. Changes in GAT-1 protein and mRNA
expression have also been described in various epilepsy
models, including the kainic acid, picrotoxin, FeCl2 models,
and in TLE patients [13,19-21].
Here we have studied the changes in EAAT-3 and GAT-
1 transporter protein expression in hippocampal cells of
the dentate gyrus (DG) and CA1 at different times after 4-
aminopyridine (4-AP) administration because it was
demonstrated that 4-AP increases the levels of glutamate
and GABA in the hippocampal extracellular space, as well
as glutamate produces hyperactivation of its receptors and
seizures [2,3,22]. Although, participation of glutamate and
GABA transporters in seizures is well documented, there is
no evidence about their contribution in this model of sei-
zures considering their possible effect in extracellular neu-
rotransmitters levels observed previously and relation with
EEG activity as well as convulsive behavior. For this reason,
we used dual immunofluorescence to determine whether
glutamate or GABA transporters co-localize with the neur-
onal marker NeuN. In parallel, we recorded EEG activity
and analyzed seizure behavior using a modified version of
the Racine Scale [23] to investigate the correlation between
seizure intensity and changes in EAAT-3/Neun or GAT-1/
Neun co-labeled cells. In addition, we chose the entorhinal
cortex (EC) in order to inject 4-AP because it produces an
epileptiform pattern in EEG recordings previously studied
in our laboratory [2,23,24]. Our results show a rapid com-
pensatory effect in the average number of cells immunola-
belled for EAAT-3 during maximum epileptiform activity
associated with a high convulsive behavior in bilateral DG
region. We conclude that this compensatory mechanism
has the purpose to increase glutamate clearance from the
extrasynaptic space due to the raise in glutamate levels
induced by K+ channel blocked effect of 4-AP. Also,
increases in GAT-1/Neun labeled DG cells observed may
facilitate increased GABA release in this region via reverse
transport, in order to enhance inhibitory effect in response
to the excitatory stimuli produced by seizures and the
effect of glutamate exposure in 4-AP treated rats, but it is




Twenty-four adult male Wistar rats (250–350 g in weight)
were used in the present study. All experimental procedureswere designed in order to minimize animal suffering and the
total number of animals used. All rats were maintained in in-
dividual cages in a temperature-controlled room, on a 12-h
light/dark cycle with ad libitum access to food and water.
This protocol was conformed to the Rules for Research in
Health Matters (Mexican Official Norms NOM-062-ZOO-
1999, NOM-033-ZOO-1995) and it was approved by the
local Animal Care Committee.
Rats were first anesthetized with isofluorane in 100% O2
and secured in a Stoelting stereotaxic frame with the incisor
bar positioned at −3.3 mm. A stainless steel guide cannula
(0.5 mm internal diameter) was implanted into each rat
through a hole drilled in the skull, and it was positioned in
the right entorhinal cortex (rEC) at the following stereotaxic
coordinates relative to bregma (rEC: AP −8 mm, L 4.6 mm,
V 4 mm). This cannula was used to insert an injection nee-
dle (V 5 mm) that also served as a recording electrode. The
cannula was insulated by varnishing the entire surface ex-
cept a 1 mm portion of its tip. Four stainless steel screws
were attached to the skull, two above bregma and two above
the cerebellum, which served as indifferent and ground elec-
trodes, respectively. Three surface electrodes with the same
characteristics as the electrodes described above were
implanted into the skull above: the left occipital cortex bin-
ocular (lOCB, AP −8 mm, L −4.6 mm relative to bregma);
and the right and left occipital cortex (rOC/lOC, AP
−5.6 mm, L 5.0 mm; AP −5.6 mm, L −5 m relative to
bregma). The guide cannula and surface electrode wires
were attached to a socket connector and fixed to the skull
with acrylic dental cement.
Drug administration and EEG recording
After surgery, the animals were allowed to recover for 24 h
and they were then divided into experimental groups as fol-
lows: 3 control groups (n = 3 per group) received an injec-
tion of the vehicle alone (NaCl, 0.9%) and 30, 60 or 180 min
after injection the animals were sacrificed; 3 experimental
groups of animals (n = 5 per group) were injected with 10
nmols 4-AP, and sacrificed similarly 30, 60 or 180 min after
injection.
4-AP (Sigma St. Louis, MO, USA) was diluted in the ap-
propriate concentration of NaCl to maintain iso-osmolarity.
Both vehicle and 4-AP solutions were injected locally into
the rEC at a flow rate of 0.5 μl/min for 2 min (final volume
1 μl) using a microsyringe mounted on a BAS microinjec-
tion pump.
The rats were placed in a container unit and the electro-
des connected to a cable fixed to a balanced arm. EEG ac-
tivity was recorded using a Grass polygraph model 6 with a
low-frequency filter at 1 Hz and a high frequency filter at
300 Hz, and it was sampled at 100 Hz/channel (four chan-
nels). Data was stored on a computer hard disk and ana-
lyzed with AcqKnowledge software from Biopac Systems
MP150 (Biopac Systems, Inc. Goleta, CA, USA). After
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(10 nmol) was administered and the animals were then
observed continuously for 30, 60 or 180 min, during which
time EEG activity was recorded. The basal electrical activ-
ity of each group was analyzed, and the amplitude and fre-
quency averaged over a 5 min recording period. The data
from the experimental groups was analyzed by measuring
the amplitude of single epileptiform discharges over a
5 min period of the recording at different times after drug
administration. The frequency of the EEG epileptiform ac-
tivity (the number of single epileptiform discharges during
a 1 sec seizure period) was averaged manually for 5 min
according to the different time periods studied. Propaga-
tion of this epileptiform activity to other areas was also
analyzed.
Behavioral study
Animal behavior was scored by continuous observation be-
fore, during and after vehicle or drug administration, using
a modified version of the Racine scale [23]. Briefly, behav-
ior was scored as follows: 0, behavioral arrest (motionless),
piloerection, excitement and rapid breathing; 1, movement
of the mouth, lips tongue and vibrissae, salivation; 2, head
and eye clonus; 3, forelimb clonus, “wet dog shakes”; 4,
clonic rearing; 5, clonic rearing with loss of postural con-
trol and uncontrolled jumping.
Perfusion and Immunofluorescence
Rats were anaesthetized with nembutal (60 mg/kg, i.p.)
and transcardially perfused with phosphate buffer saline
(PBS, 0.1 M, pH 7.4, 37 °C), followed by 4% paraformal-
dehyde (in 0.1 M PBS, pH 7.4) containing 0.1% glutaral-
dehyde. The animal’s brain was removed and post-fixed
for 12 to 16 h at 4 °C. The brains were then mounted on
a vibratome (Leica, VT1000S, Germany) and sliced cor-
onally at a thickness of 50 μm. These sections were col-
lected consecutively in separate wells of an incubation
chamber containing PBS.
Antibodies directed against the EAAT-3 glutamate
transporter (rabbit polyclonal antiserum, c-terminal
amino acids 455–524 of human EAAT-3: Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) and the GAT-1
GABA transporter (rabbit polyclonal antiserum, c-terminal
amino acids 588–599 of rat GAT-1: Chemicon Inter-
national, Temecula, CA) were used. A monoclonal NeuN
antiserum (Chemicon International) was used to identify
neurons.
Immunofluorescence was performed as described previ-
ously [25]. Briefly, EAAT-3 and GAT-1 immunofluores-
cence was performed using PBS and TRIS-buffer saline
(TBS; 0.1 M, pH 7.4), respectively, in conjunction with the
NeuN antibody. Tissue sections were washed twice for
15 min in PBS or TBS with agitation and they were then
incubated for 2 h at room temperature with 5% normalgoat serum (NGS) in PBS or TBS. After two 15 min
washes, the sections were incubated for 72 h at 2-8°C with
combinations of the primary antibodies (anti-EAAT-3,
1:500; anti-GAT1, 1:250; and anti-NeuN, 1:1000) diluted in
PBS or TBS containing 5% NGS and 0.3% Triton X-100.
The sections were then washed five times with agitation for
10 min in PBS or TBS and incubated with the secondary
antibody with agitation for 2 h in darkness at room
temperature. EAAT-3 and GAT1 were detected using goat
anti-rabbit IgG-Alexa 594 (1:500: Invitrogen, Oregon, USA)
in PBS or TBS containing 5% NGS, respectively, while
NeuN was identified using a goat anti-mouse IgG-Alexa 488
(1:500: Invitrogen, Oregon, USA). Sections were washed five
times with agitation for 15 min each in PBS or TBS [8,18]
before mounting on glass slides and coverslipping using vec-
tashield to preserve fluorescence. The sections were exam-
ined by fluorescence microscopy (Olympus, U-LH100HG,
Japan) and analyzed using Photoshop CS4 software. Control
sections were incubated without primary antibody or by re-
placing the primary antibody with normal rabbit serum, and
no fluorescent signal was observed in any of the control sec-
tions (data not shown).
Cell counting
As described previously [25], the number of cells was calcu-
lated by manual observation of fluorescence microscopy
images using Photoshop CS4 software (Version 11.0). Cells
of the DG or CA1 region of the hippocampus were counted
in merged images of double-labelled sections (EAAT-3/
NeuN or GAT-1/NeuN) using a 40x objective (5 images for
each transporter in each animal). Counting was restricted
to a defined area of tissue (DG or CA1) using a modifica-
tion of West’s method [26]. Briefly, a number of slices at
uniform intervals were selected from the total number of
slices obtained per region (5 slices were selected from a
total of 10 per animal) and the total number of co-labelled
neurons in the DG or CA1 was counted using an optical
dissector (height = 0.01 mm). This systematic scanning was
performed in 50 μm slices over a defined region of interest
with an area of 35,200 μm2 (based on the objective used
and the image area captured). The number of cells counted
in the optical dissector was then corrected according to the
counting area, the proportion of the slices analysed (50%)
and the thickness of the slice, providing a total value for the
region of interest.
Histological evaluation
To verify the location of the guide cannula in each experi-
ment, some coronal brain sections (50 mm thick) were
taken from rats previously perfused to immunofluores-
cence and belonging to different experimental and control
groups, then stained with cresyl violet and if the cannula
was implanted incorrectly the animals were excluded from
the study.
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Comparative analysis of the experimental and control
groups was performed using a one-way analysis of variance
(ANOVA) and a Tukey-Kramer post hoc test. A paired Stu-
dent´s t test was used to compare control and experimental
groups at equivalent time points. The Mtab13 statistical
software package was used for all analyses. Results were
considered statistically significant at p <0.05.
Results
EEG activity and seizure behavior in animals
In vehicle-treated animals, EEG activity was characterized
by the presence of slow physiological waves of low ampli-
tude and frequency, similar to the basal EEG activity in
the animals administered 4-AP (Figures 1 and 2). No
convulsive behavior was observed in the control animals
that received the vehicle alone, and they displayed only
sporadic tidying and scratching behavior before and afterFigure 1 Representative EEG recordings at different time-points after
in a 4-AP rat before and 30 min after 4-AP administration, and in a control
4-AP rat before, 30 and 60 min after 4-AP administration, and in a control r
4-AP rat before, 30, 60, 120, and 180 min after 4-AP administration, and in
left occipital cortex (rOC/lOC), right entorhinal cortex (rEC) and left occipitaNaCl administration. 4-AP administration to the rEC (n =
15) induced epileptiform activity, which was characterized
by the presence of trains of poly-spikes and low amplitude
and frequency spike-wave complexes that became more in-
tense during the course of the experiment. The first epilep-
tiform discharge was observed in the rEC (134 ± 86.4 s),
and then in the lOC (151 ± 79.5 s), lOCB (263 ± 136 s)
and finally in the rOC (266 ±136 s).
The maximum amplitude and frequency of epileptiform
activity was observed between 30 and 60 min after 4-AP
administration in animals sacrificed at 180 min, and it was
associated with a score of 3–4 on the modified Racine
Scale [23] (Table 1). In this experimental group, epilepti-
form activity decreased in amplitude, particularly between
90 and 120 min after 4-AP administration, returning to
basal levels 180 min after 4-AP administration (Figures 1
and 2). These animals received scores of 1, 2 or 3 on the
modified Racine scale at the end of experiment.vehicle (NaCl) or 4-AP administration. A) Left to right; EEG activity
rat 30 min after NaCl administration. B) Left to right; EEG activity in a
at 60 min after NaCl administration. C) Left to right; EEG activity in a
a control rat 180 min after NaCl administration. Abbreviations: right and
l cortex binocular (lOCB).
Figure 2 Changes in the amplitude and frequency of EEG activity after 4-AP injection. Graphs represent the three experimental groups of
animals sacrificed at 30 (graphs in top), 60 (graphs in middle) and 180 (graphs in bottom) min after 4-AP administration. The time course is
represented on the x-axis, while the y-axis represents the data as percentage of change with respect to electrical basal activity (100%) of 24
control animals. Error bars represent SEM. Abbreviations: right and left occipital cortex (blue diamond rOC / red square lOC), right entorhinal
cortex (green triangle rEC) and left occipital cortex binocular (violet asterisk lOCB).
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EAAT-3 labeling was observed around the soma and
dendrites of granule cells in the DG and pyramidal cells
in the CA region, both in control and experimental ani-
mals (Figure 3). There were no significant differences in
the number in EAAT-3/NeuN dual labeled cells observed
in experimental and control animals sacrificed 30 min after
injection (Figure 4). However, more EAAT-3/NeuN dual
labeled cells were evident in the DG of animals sacrificed
60 min post 4-AP injection than in control animals (right
DG (rDG), 2931 ± 52 vs. 2457 ± 178; left DG (lDG), 2980
± 14 vs. 2253 ± 42 co-labeled cells/mm3, p<0.001) that rep-
resent 19% and 32% of change in the rDG and lDG, re-
spectively. In parallel, we observed a decrease in the
number of EAAT-3/NeuN co-labeled cells in the CA1 of
4-AP-treated animals when compared with controls (rightCA1 (rCA1), 1145 ± 18 vs.1327 ± 31; left CA1 (lCA1),
1059 ± 16 vs. 1217 ± 21 co-labeled cells/mm3, p<0.001),
this is 14% and 13% of change in the rCA1 and lCA1, re-
spectively. In animals sacrificed 180 min after 4-AP injec-
tion, the number of CA1 pyramidal cells expressing EAAT-
3 decreased when compared with the control animals
(rCA1, 927 ± 14 vs. 992 ± 23; lCA1, 915 ± 11 vs. 956 ± 17
co-labeled cells/mm3, p<0.05), that represent 7% of change
in rCA1 and 5% in lCA1. By contrast, no significant
changes were observed in the DG region.
Effect of 4-AP on GAT-1 colabelling
GAT-1 labeling was observed around the soma of granule
cells in the DG and pyramidal cells in CA1, both in control
and 4-AP-treated animals (Figure 3). No significant changes
in GAT-1/NeuN colabelling were observed in either region
Table 1 Seizure behavior of the three groups of rats
following intra-rEC administration of 4-AP
(10 nmol, n = 5 per group)
Behavior after 4 AP Injection
RAT Minutes
15 30 45 60 120 180
1–5 (A) 0/1/2/3 0/1/2/3
6–10 (B) 0/1/2 0/1/2/3/4 0/1/2/3/4 0/1/2/3
11–15 (C) 0/1/2/3 1/2/3/4 0/1/2/3/4 0/1/2/3/4 0/1/2/3 0/1/2/3
The values represent seizure behavior according to the modified Racine Scale
[23]: 0, behavioral arrest (motionless), piloerection, excitement and rapid
breathing; 1, movement of the mouth, lips tongue and vibrissae, salivation; 2,
head clonus and eye clonus; 3, forelimb clonus, “wet dog shakes”; 4, clonic
rearing; 5, clonic rearing with loss of postural control and uncontrolled
jumping.
The rats were sacrificed 30 (A), 60 (B) or 180 (C) min after 4-AP injection.
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30 min (Figure 4). However, 60 min after 4-AP administra-
tion we observed an increase in the number of GAT-1 la-
beled cells in the DG and CA1 when compared with
vehicle-treated animals (rDG, 2656 ± 36 vs. 2364 ± 42;
lDG, 2949 ± 24 vs. 2058 ± 44; rCA1, 1155 ± 23 vs. 1055
± 6; lCA1 1090 ± 11 vs. 1032 ± 10 co-labeled cell/mm3,
p<0.05), this is 12% and 43% of change in rDG and lDG, re-
spectively, while in rCA1 and lCA1 was observed 9% and
5% of change. In animals sacrificed 180 min after 4-AP in-
jection, the number of GAT-1 labeled cells in the DG
decreased when compared with vehicle-treated animals
(rDG, 2270 ± 19 vs. 2329 ± 8; lDG, 2224 ± 60 vs. 2468 ± 87
co-labeled cells/mm3, p<0.05), that represent 3% and 10%
of change in rDG and lDG, respectively, while there were
no changes in GAT-1 in the CA1.
Discussion
Local administration of 4-AP into the rEC induced epilepti-
form activity characterized by poly-spike trains and spike-
wave complexes, peaking between 30 and 60 min after
4-AP administration, and consistent with previous studies
in our laboratory [23,24]. Moreover, the maximal EEG ac-
tivity coincided with convulsive behavior that was asso-
ciated with a score of 3/4 on the modified Racine Scale
[23]. Epileptiform discharges were first detected in the rEC,
followed by the lOC and lOCB, and finally in the rOC.
EAAT-3 colabelling was detected in the soma and den-
drites of dentate granule cells and pyramidal cells of con-
trol groups. In agreement with our study, Holmseth et al.
[27] detected EAAT-3 labeling intracellularly in soma and
dendrites in DG of hippocampus, they estimated the mean
EAAT-3 density (90 molecules/μm2) in dendritic mem-
brane but the most of the EAAT-3 was located intracellu-
larly assuming that EAAT-3 is evenly distributed. Animals
sacrificed 30 min after 4-AP administration exhibited no
changes in the average number of cells immunolabelled for
EAAT-3 or GAT-1, in either the CA1 or DG. However,60 min after 4-AP-induced epileptiform activity, the num-
ber of EAAT-3/NeuN co-labeled cells increased bilaterally
in the DG while decreased in CA1. The present findings
are supported by early studies describing decreased EAAT-
3 immunolabeling in rat pyramidal cells of CA1 just 4 h
after seizure onset produced by kainic acid administration
[28]. Increased EAAT-3 immunoreactivity (IR) in granule
cells of DG during the acute epileptic phase (24 h) was
observed in the animal model of status epilepticus (SE)
induced by electrical stimulation [29], and increases in
EAAT-3 and GAT-1 IR have been described in granular
and pyramidal cells of hippocampal sections from TLE
patients [13,14]. Although, these last data cannot be dir-
ectly compared with the present results, all these findings
indicate important changes in expression of EAAT-3 trans-
porter during seizures and epilepsy. The decreases in CA1
EAAT-3 labeled cells described here contrast with the
increases in EAAT-3 IR neurons in the CA1-3 of animals
with SE reported previously [29]. This discrepancy may be
due to differences in the protocols used to induce seizures,
in the EAAT-3 antibodies used and in the time between
seizure induction and tissue processing, further increasing
the potential divergence in the results.
CA1 and CA3 neurons have already been described to be
more susceptible to seizures than those in other CA regions
[30,31] and neuronal damage in CA1/CA3 was observed
after 4-AP injection in hippocampus [32] that contrast with
abundant NMDA receptors found in this region [33], simi-
larly antagonists to this receptor protects against seizures
and damage [34,35]. These early studies support our results
about decreased EAAT-3 labeled cells observed in CA1. In-
deed, kainic acid administration decreases EAAT-3 IR and
EAAT-3 mRNA expression in CA1 pyramidal cells [28].
Together, these findings suggest a rapid down regulation of
EAAT-3 transporter expression in the CA1 during seizures.
Considering that only 20-30% of EAAT-3 is localized at
the plasma membrane [36,37] and the intracellular EAAT-
3 can be inserted rapidly into the plasma membrane in re-
sponse to activity or pathological conditions like seizures
[36,38,39], the increase of EAAT-3 in soma of granule cells
found 60 min after seizures induced by 4-AP could func-
tion as a available pool of EAAT-3 for redistribution to the
plasma membrane to facilitates the capture as well as the
clearance of glutamate excess from the extrasynaptic space,
particularly given the localization of EAAT-3 transporters
in asymmetrical and symmetrical synapses in the soma and
dendrites of granule cells [8,10]. This hypothesis is sup-
ported by our previous studies where an increase in extra-
cellular glutamate levels (up 400% of change with respect
to the baseline) in hippocampus was observed during the
first epileptiform discharge after 4-AP (10 nmol) injection
into the EC, these increases in glutamate levels were
decreased as the seizure progress and at 60 min after 4-AP
administration, glutamate concentrations were returned to
Figure 3 (See legend on next page.)
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Figure 3 Representative fluorescence microscopy images obtained from control and experimental animals where it is observed NeuN,
EAAT-3 or GAT-1 labeled cells, as well as co-labeled cells (NeuN/EAAT-3 or NeuN/GAT-1) in various brain regions: A and C) in right CA1
(rCA1); B and D) in right dentate gyrus (rDG). Scale bar = 50 μm.
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obtained here [4,40]. In addition, the methodologies used
in these studies (an electrochemical biosensor and enzym-
atic reactor with electrochemical detection) allowed us to
improve time resolution of about 1 min per microdialysis
sample [4,40]. Also, co-expression of the NMDA glutamate
receptor with the EAAT-3 transporter in Xenopus oocytes
decreases the activation of the former [41], suggesting a
protective role of the EAAT-3 transporter in excitotoxic
conditions and in co-operation with the cysteine/glutamate
antiporter Xc
-, the EAAT-3 transporter helps to protect
neuronal HT22 cells (an immortalized hippocampal cell
line) from oxidative glutamate toxicity [11]. Increases inFigure 4 Number of co-labelled cells per mm3 in the different brain r
(bottom) min after vehicle or 4-AP administration. Abbreviations as inEAAT-3/NeuN colabelling in dentate granular cells may
also enhance inhibitory activity by increasing GABA syn-
thesis. In agreement, the GAD/GABA markers in granule
cells are transiently up-regulated in response to seizures
[42,43]. The EAAT-3 transporter also participates in the
rapid adaptation of pre-synaptic inhibitory terminals to
alterations in local network activity by replenishing vesicu-
lar glutamate content, which can then be converted to
GABA for release [44,45]. Furthermore, kindled seizures
induce GABAergic fast synaptic inhibition in the mossy
fibers of the DG to CA3 system [46].
Animals sacrificed 180 min after 4-AP injection exhibited
bilateral decreases in the average number of EAAT-3/NeuNegions of animals sacrificed 30 (top), 60 (middle) and 180
Figure 3.
Medina-Ceja et al. Journal of Biomedical Science 2012, 19:78 Page 9 of 11
http://www.jbiomedsci.com/content/19/1/78co-labeled pyramidal cells in the CA1. Decreased EAAT-3
IR was also described previously in rat CA1 pyramidal cells
4 hours after KA treatment [28] and diminished EAAT-3
mRNA expression was reported in the rat hippocampus 4 h
after ferric chloride treatment [47]. Taken together, these
results suggest a rapid down regulation of EAAT-3 trans-
porter during seizures induced by diverse chemical agents.
The decrease in the average number of EAAT-3/NeuN co-
labeled pyramidal cells from 60 to 180 min after 4-AP ad-
ministration supports the hypothesis that CA1 neurons are
highly susceptible to seizures. However, decreased EAAT-3
transporter expression can induce seizures, as seen when
using an anti-sense oligopeptide antibody to EAAT-3 [48].
In the present study, maximum seizure intensity and con-
vulsive behavior elicited by a low dose of 4-AP (10 nmols)
was correlated with a rapid up-regulation of EAAT-3/NeuN
colabelling 60 min after 4-AP injection. It is established that
4-AP increase extracellular levels of glutamate that originate
from pre-synaptic nerve endings to produce an overactivation
of glutamate receptors and subsequent seizures as well as
neurodegeneration of the CA1, CA2 and CA3 hippocampal
subfields [2,3] This effect is blocked by glutamate receptor
antagonists of both the NMDA and the non-NMDA types
in vivo as in vitro experiments [34,49]. Also it is known that
CA1 contains a high expression of NMDA receptors [50].
EAAT-3 as a neuronal transporter, not only to uptake glutam-
ate from synaptic cleft to maintain of low extracellular glu-
tamate, also it contributes to multiple aspects of synaptic
signaling: EAAT-3 limits glutamate spillover and participates
to neuronal uptake of cysteine, a critical precursor for gluta-
thione synthesis and importantly EAAT-3 can attenuate the
activation of perysinaptic NMDA receptors [41,51]. With base
in these arguments and as an effect caused by 4-AP, the in-
crease in EAAT-3 colabelled cells in DG after 60 min post-
seizures induced by 4-AP could function as an available pool
of EAAT-3 for redistribution to the plasma membrane to fa-
cilitate the capture as well as the clearance of glutamate excess
from the extrasynaptic space to attenuate the overactivation
of perysinaptic NMDA receptors. This compensatory mech-
anism has the purpose to attenuate seizures and the asso-
ciated convulsive behavior; these latter effects were observed
180 min after 4-AP injection (Figure 1C, 2 and Table 1).
GAT-1 colabelling was detected in the soma and den-
drites of dentate granule cells and pyramidal cells, in agree-
ment with previous studies [20,52]. Bilateral increases in
the number of GAT-1/NeuN co-labeled cells in the DG
and CA1 were observed in this study. These results are
related with significant increases of GAT-1 mRNA found
bilaterally in the hippocampal DG at 1 h after kindled
generalized seizures [53]. In addition, this up-regulation of
GAT-1/NeuN colabelling observed 60 min after 4-AP ad-
ministration may augment GABA release into the synaptic
cleft via reverse transport, counteracting the excitatory
activity produced by glutamate release induced by 4-AP.This hypothesis is supported by the following experimental
evidences. Reverse transport via GAT-1 transporters has
been described in cultured hippocampal neurons, where it
facilitates phasic inhibition through the activation of
GABA-A receptors in both normal and pathological condi-
tions [54,55]. GAT-1 reverse transport and activation of
nearby GABA receptors have also been reported in glia
[55,56]. Given the dual role of granule cells in GABA and
glutamate neurotransmission during seizures [46] reverse
transport via GAT-1 may increase GABA release from den-
tate granule cells, thereby reducing hyperactivity and seiz-
ure activity in this region. In addition, previous studies
have demonstrated that 4-AP increase GABA levels in
hippocampus at different 4-AP concentrations during and
after 4-AP administration [22,57]. However, it is necessary
additional experimental work using a high time resolution
methodology to confirm a better relation between GABA
levels, EEG activity and GAT-1 labeling throughout sei-
zures induced by 4-AP. Finally, we observed a decrease in
GAT-1/NeuN colabelling in dentate granule cells 180 min
after seizure induction, which was accompanied by a de-
crease in seizure activity. Although, we cannot compare
the decrease of GAT-1 observed 180 min after 4-AP treat-
ment with other studies, since there are not available data
in this matter, we could suggest that the rapid upregulation
of GAT-1 labeled cells seen in the DG and CA1 at 60 min
was sufficient to abolish epileptiform discharges in these
regions as well as the seizure behavior of animals observed
180 min after 4-AP.
Conclusion
Our results provide evidence that the average number of
cells immunolabelled for EAAT-3 is rapidly up-regulated in
dentate granule cells during acute seizures. We propose
that this represents a protective and compensatory adapta-
tion to enabling more rapid and efficient removal of glu-
tamate from the extrasynaptic space induced by 4-AP and
thus attenuating seizure activity. The increase in EAAT-3/
NeuN colabelling may also enhance inhibitory activity in
dentate granule cells by increasing GABA synthesis, further
counteracting the hyperexcitation of glutamate. Also, our
results reveal a high degree of seizure susceptibility in CA1
pyramidal cells, as demonstrated by a decrease in EAAT-3
expression in this region. Finally, the increase in GAT-1/
NeuN colabelling observed in DG cells may facilitate
increased GABA release in this region via reverse transport,
further attenuating seizure activity, but it is necessary add-
itional experimental work to confirm this hypothesis.
Together, these findings contribute to our understanding of
the role of glutamate and GABA transporters in acute sei-
zures particularly induced by 4-AP.
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